<?xml version='1.0' encoding='utf-8'?>
<document id="28173639"><sentence text="Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes."><entity charOffset="0-8" id="DDI-PubMed.28173639.s1.e0" text="Bosentan" /><entity charOffset="13-21" id="DDI-PubMed.28173639.s1.e1" text="Rifampin" /><pair ddi="false" e1="DDI-PubMed.28173639.s1.e0" e2="DDI-PubMed.28173639.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28173639.s1.e0" e2="DDI-PubMed.28173639.s1.e1" /></sentence><sentence text="The incidence of polypharmacy-which can result in drug-drug interactions-has increased in recent years" /><sentence text=" Drug-metabolizing enzymes and drug transporters are important polypharmacy modulators" /><sentence text=" In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro"><entity charOffset="31-39" id="DDI-PubMed.28173639.s4.e0" text="bosentan" /><entity charOffset="44-52" id="DDI-PubMed.28173639.s4.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28173639.s4.e0" e2="DDI-PubMed.28173639.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28173639.s4.e0" e2="DDI-PubMed.28173639.s4.e1" /></sentence><sentence text=" HEK293 cells and primary human hepatocytes overexpressing the target genes were treated with bosentan and various concentrations of rifampin, which decreased the uptake activities of OATP transporters in a dose-dependent manner"><entity charOffset="94-102" id="DDI-PubMed.28173639.s5.e0" text="bosentan" /><entity charOffset="133-141" id="DDI-PubMed.28173639.s5.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28173639.s5.e0" e2="DDI-PubMed.28173639.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28173639.s5.e0" e2="DDI-PubMed.28173639.s5.e1" /></sentence><sentence text=" In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with 20 μM bosentan+200 μM rifampin"><entity charOffset="132-140" id="DDI-PubMed.28173639.s6.e0" text="rifampin" /></sentence><sentence text=" Rifampin also reduced gene expression of OATP1B1, OATP1B3, and OATP2B1 transporter, and inhibited bosentan influx in human hepatocytes at increasing concentrations"><entity charOffset="1-9" id="DDI-PubMed.28173639.s7.e0" text="Rifampin" /><entity charOffset="99-107" id="DDI-PubMed.28173639.s7.e1" text="bosentan" /><pair ddi="false" e1="DDI-PubMed.28173639.s7.e0" e2="DDI-PubMed.28173639.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28173639.s7.e0" e2="DDI-PubMed.28173639.s7.e1" /></sentence><sentence text=" These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450"><entity charOffset="23-32" id="DDI-PubMed.28173639.s8.e0" text="rifampin-" /><entity charOffset="37-45" id="DDI-PubMed.28173639.s8.e1" text="bosentan" /><pair ddi="false" e1="DDI-PubMed.28173639.s8.e0" e2="DDI-PubMed.28173639.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28173639.s8.e0" e2="DDI-PubMed.28173639.s8.e1" /></sentence><sentence text="" /></document>